A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
References to “Roivant,” the “Company,” “we,” “us” or “our” in the following section refer to Roivant Sciences Ltd. and its consolidated subsidiaries, unless the context otherwise requires. Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 13M | - | - | - | - | - |
| Net Income | -809M | -172M | 4.3B | 4.3B | -845M | -809M |
| EPS | $-1.17 | $-0.24 | $5.23 | $5.23 | $-1.26 | $-0.43 |
| Free Cash Flow | -767M | -844M | 761M | 831M | -695M | -558M |
| ROIC | -18.4% | - | 84.0% | 110.7% | -45.3% | - |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | - | 0.16 | 0.07 | 0.13 | - |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -1.2B | -1.0B | 4.5B | 4.2B | -1.4B | -1.1B |
| Operating Margin | -9130.5% | - | - | - | - | - |
| ROE | -19.0% | - | 81.6% | 114.1% | -51.0% | - |
| Shares Outstanding | 716M | 717M | 832M | 832M | 671M | 1,897M |
| Metric | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | 13M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 237M | 483M | 454M | 440M | 550M | 628M |
| SG&A | 260M | 775M | 601M | 687M | 591M | 599M |
| EBIT | -1.1B | -1.4B | 4.2B | 4.5B | -1.0B | -1.2B |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | -9130.5% |
| Net Income | -809M | -845M | 4.3B | 4.3B | -172M | -809M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | -6079.9% |
| Non-Recurring | 0 | 444M | 0 | 5.3B | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | N/A | -45.3% | 110.7% | 84.0% | N/A | -18.4% |
| ROE | N/A | -51.0% | 114.1% | 81.6% | N/A | -19.0% |
| ROA | N/A | -32.7% | 88.7% | 68.7% | N/A | -15.5% |
| Cash Flow | ||||||
| Op. Cash Flow | -552M | -678M | 843M | 765M | -839M | -759M |
| Free Cash Flow | -558M | -695M | 831M | 761M | -844M | -767M |
| Owner Earnings | -637M | -1.2B | 607M | 544M | -1.1B | -1.1B |
| CapEx | 5.8M | 17M | 13M | 4.6M | 4.6M | 7.8M |
| Maint. CapEx | 0 | 5.9M | 19M | 22M | 14M | 4.1M |
| Growth CapEx | N/A | 12M | 0 | 0 | 0 | 3.6M |
| D&A | 0 | 5.9M | 19M | 22M | 14M | 4.1M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 2.2M | 2.2M | 1.3B | 1.3B | 504M |
| Buyback Yield | N/A | N/A | N/A | N/A | 17.4% | 2.4% |
| Stock-Based Comp | 85M | 565M | 218M | 200M | 289M | 352M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | N/A | -1.9B | -6.1B | N/A | N/A | -4.5B |
| Cash & Equiv. | N/A | 2.1B | 6.5B | 2.7B | N/A | 4.5B |
| Long-Term Debt | N/A | 210M | 431M | N/A | N/A | N/A |
| Debt/Equity | N/A | 0.13 | 0.07 | 0.16 | N/A | 0.00 |
| Interest Coverage | -381.2 | -192.0 | 151.7 | 129.3 | -168.3 | -168.3 |
| Equity | N/A | 1.7B | 6.0B | 4.7B | N/A | 4.3B |
| Total Assets | N/A | 2.6B | 7.2B | 5.4B | N/A | 5.2B |
| Total Liabilities | N/A | 524M | 774M | 749M | N/A | 251M |
| Intangibles | N/A | N/A | 138M | N/A | N/A | N/A |
| Retained Earnings | N/A | -2.8B | 576M | 116M | N/A | -695M |
| Working Capital | N/A | 2.0B | 6.5B | 4.9B | N/A | 4.5B |
| Current Assets | N/A | 2.1B | 6.7B | 5.0B | N/A | 4.7B |
| Current Liabilities | N/A | 184M | 267M | 149M | N/A | 152M |
| Per Share Data | ||||||
| EPS | -0.43 | -1.26 | 5.23 | 5.23 | -0.24 | -1.17 |
| Owner EPS | -0.34 | -1.86 | 0.73 | 0.65 | -1.59 | -1.56 |
| Book Value | N/A | 2.47 | 7.18 | 5.64 | N/A | 5.97 |
| Cash Flow/Share | -0.29 | -1.01 | 1.01 | 0.92 | -1.17 | -1.12 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 1.9B | 670.8M | 831.5M | 831.5M | 716.6M | 715.7M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | N/A | 2.0 | N/A | -24.9 |
| P/FCF | N/A | N/A | 7.4 | 11.5 | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 3.4 | 1.9 | 4.5 | 1.5 | 1.6 | 4.9 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | -9.0% | -21.7% | 15.9% | 8.7% | -11.3% | -3.7% |
| Market Cap | 6.2B | 3.2B | 5.2B | 8.8B | 7.4B | 20.8B |
| Avg. Price | 10.15 | 8.75 | 5.36 | 10.16 | 11.25 | 29.12 |
| Year-End Price | 9.79 | 4.78 | 7.35 | 10.54 | 10.38 | 29.12 |
Roivant Sciences Ltd. passes 3 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average ROIC is 49.8%. Total shareholder yield (buybacks) is 2.4%. At current prices, the estimated annualized return to fair value is -2.3%.
Roivant Sciences Ltd. (ROIV) has a 5-year average return on invested capital (ROIC) of 49.8%. This indicates strong capital allocation and a potential competitive advantage.
Roivant Sciences Ltd. (ROIV) has a market capitalization of $20.8B. It is classified as a large-cap stock.
Roivant Sciences Ltd. (ROIV) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 2.42%.
Roivant Sciences Ltd. (ROIV) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Roivant Sciences Ltd. (ROIV) generated $-844 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Roivant Sciences Ltd. (ROIV) reported earnings per share (EPS) of $-0.24 in its most recent fiscal year.
The Ledger Terminal provides 5 years of financial data for Roivant Sciences Ltd. (ROIV), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
No recent press releases.